Development and screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene delivery properties

References

• Lykken EA, Shyng C, Edwards RJ, Rozenberg A, Gray SJ. Recent progress and considerations for AAV gene therapies targeting the central nervous system. J Neurodev Disord. 2018;10(1):1–10. doi:10.1186/s11689-018-9234-029329511
   PubMedGoogle Scholar
• Costantini LC, Bakowska JC, Breakefield XO, Isacson O. Gene therapy in the CNS. Gene Ther. 2000;7(2):93–109. doi:10.1038/sj.gt.330111910673714
   PubMed Web of Science ®Google Scholar
• Pardo J, Morel GR, Astiz M, et al. Gene therapy and cell reprogramming for the aging brain : achieve- ments and promise. Curr Gene Ther. 2014;14(1):24–34.24450294
   PubMed Web of Science ®Google Scholar
• Furtado D, Björnmalm M, Ayton S, Bush AI, Kempe K, Caruso F. Overcoming the blood–brain barrier: the role of nanomaterials in treating neurological diseases. Adv Mater. 2018;30:46. doi:10.1002/adma.201801362
   Web of Science ®Google Scholar
• Hersh DS, Wadajkar AS, Roberts N, et al. Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier. Curr Pharm Des. 2016;22(9):1177-1193. doi:10.2174/1381612822666151221150733.
   Google Scholar
• Vieira DB, Gamarra LF. Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier. Int J Nanomedicine. 2016;11:5381–5414. doi:10.2147/IJN.S11721027799765
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood – brain barrier delivery. Drug Discov Today. 2007;12(January):54–61. doi:10.1016/j.drudis.2006.10.01317198973
   PubMedGoogle Scholar
• Pandey PK, Sharma AK, Gupta U. Blood brain barrier: an overview on strategies in drug delivery, realistic in vitro modeling and in vivo live tracking. Tissue Barriers. 2016;4(1):1–14. doi:10.1080/21688370.2015.1129476
   Google Scholar
• Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release. 2017;264(July):306–332. doi:10.1016/j.jconrel.2017.08.03328844756
   PubMedGoogle Scholar
• Agrawal M, Ajazuddin AA, Tripathi DK, et al. Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of alzheimer’s disease. J Control Release. 2017;260(April):61–77. doi:10.1016/j.jconrel.2017.05.01928549949
   PubMedGoogle Scholar
• Paterson J, Webster CI. Exploiting transferrin receptor for delivering drugs across the blood-brain barrier. Drug Discov Today Technol. 2016;20:49–52. doi:10.1016/j.ddtec.2016.07.00927986223
   PubMedGoogle Scholar
• Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 1999;31(10):1111–1137. doi:10.1016/S1357-2725(99)00070-9
   Google Scholar
• Leitner DF, Connor JR. Functional roles of transferrin in the brain. Biochim Biophys Acta. 2012;1820(3):393–402. doi:10.1016/j.bbagen.2011.10.01622138408
   PubMedGoogle Scholar
• Johnsen KB, Burkhart A, Melander F, et al. Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma. Sci Rep. 2017;7(1):1–13. doi:10.1038/s41598-017-11220-128127051
   PubMedGoogle Scholar
• da Cruz MTG, Cardoso ALC, de Almeida LP, Simões S, de Lima MCP. Tf-lipoplex-mediated NGF gene transfer to the CNS: neuronal protection and recovery in an excitotoxic model of brain injury. Gene Ther. 2005;12(16):1242–1252. doi:10.1038/sj.gt.330251615815700
   PubMed Web of Science ®Google Scholar
• Zheng C, Ma C, Bai E, Yang K, Xu R. Transferrin and cell-penetrating peptide dual-functioned liposome for targeted drug delivery to glioma. Int J Clin Exp Med. 2015;8(2):1658–1668.25932094
   PubMed Web of Science ®Google Scholar
• Lee SM, Kim J-S, Oh Y-K, Lee Y-B, Sah H. Biodistribution and genotoxicity of transferrin- conjugated liposomes/DNA complexes in mice. Macromol Res. 2005;13(3):218–222. doi:10.1007/BF03219055
   Web of Science ®Google Scholar
• Zhang D, Wang J, Xu D. Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems. J Control Release. 2016;229(81170255):130–139. doi:10.1016/j.jconrel.2016.03.02026993425
   PubMedGoogle Scholar
• Bashyal S, Noh G, Keum T, Choi YW, Lee S. Cell penetrating peptides as an innovative approach for drug delivery; then, present and the future. J Pharm Investig. 2016;46(3):205–220. doi:10.1007/s40005-016-0253-0
   Google Scholar
• Copolovici DM, Langel K, Eriste E, Langel Ü. Cell-penetrating peptides: design, synthesis, and applications. ACS Nano. 2014;8(3):1972–1994. doi:10.1021/nn405726924559246
   PubMed Web of Science ®Google Scholar
• Guidotti G, Brambilla L, Rossi D. Cell-penetrating peptides: from basic research to clinics. Trends Pharmacol Sci. 2017;38(4):406–424. doi:10.1016/j.tips.2017.01.00328209404
   PubMed Web of Science ®Google Scholar
• Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 1988;55(6):1189–1193. doi:10.1016/0092-8674(88)90263-22849510
   PubMed Web of Science ®Google Scholar
• Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell. 1988;55(6):1179–1188. doi:10.1016/0092-8674(88)90262-02849509
   PubMed Web of Science ®Google Scholar
• Ramsey JD, Flynn NH. Cell-penetrating peptides transport therapeutics into cells. Pharmacol Ther. 2015;154:78–86. doi:10.1016/j.pharmthera.2015.07.00326210404
   PubMed Web of Science ®Google Scholar
• Simon MJ, Gao S, Kang WH, Banta S, Morrison B. TAT-mediated intracellular protein delivery to primary brain cells is dependent on glycosaminoglycan expression. Biotechnol Bioeng. 2009;104(1):10–19. doi:10.1002/bit.2237719449355
   PubMedGoogle Scholar
• Malhotra M, Tomaro-Duchesneau C, Prakash S. Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials. 2013;34(4):1270–1280. doi:10.1016/j.biomaterials.2012.10.01323140978
   PubMed Web of Science ®Google Scholar
• Qin Y, Chen H, Yuan W, et al. Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm. 2011;419(1–2):85–95. doi:10.1016/j.ijpharm.2011.07.02121807083
   PubMedGoogle Scholar
• Qin Y, Chen H, Zhang Q, et al. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm. 2011;420(2):304–312. doi:10.1016/j.ijpharm.2011.09.00821945185
   PubMedGoogle Scholar
• Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today. 2012;17(15–16):850–860. doi:10.1016/j.drudis.2012.03.00222465171
   PubMed Web of Science ®Google Scholar
• Stalmans S, Bracke N, Wynendaele E, et al. Cell-penetrating peptides selectively cross the blood-brain barrier in vivo. PLoS One. 2015;10(10):1–22. doi:10.1371/journal.pone.0139652
   Web of Science ®Google Scholar
• Gomez JA, Chen J, Ngo J, et al. Cell-penetrating penta-peptides (CPP5s): measurement of cell entry and protein-transduction activity. Pharmaceuticals. 2010;3(12):3594–3613. doi:10.3390/ph312359421359136
   PubMedGoogle Scholar
• Gomez JA, Gama V, Yoshida T, et al. Bax-inhibiting peptides derived from Ku70 and cell-penetrating pentapeptides. Biochem Soc Trans. 2007;35(Pt4):797–801. doi:10.1042/BST035079717635151
   PubMedGoogle Scholar
• Yoshida T, Tomioka I, Nagahara T, et al. Bax-inhibiting peptide derived from mouse and rat Ku70. Biochem Biophys Res Commun. 2004;321(4):961–966. doi:10.1016/j.bbrc.2004.07.05415358121
   PubMedGoogle Scholar
• Cai D, Gao W, He B, et al. Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy. Biomaterials. 2014;35(7):2283–2294. doi:10.1016/j.biomaterials.2013.11.08824360410
   PubMed Web of Science ®Google Scholar
• Li X, Ding L, Xu Y, Wang Y, Ping Q. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm. 2009;373(1–2):116–123. doi:10.1016/j.ijpharm.2009.01.02319429296
   PubMed Web of Science ®Google Scholar
• dos Santos Rodrigues B, Oue H, Banerjee A, Kanekiyo T, Singh J. Dual functionalized liposome-mediated gene delivery across triple co-culture blood brain barrier model and specific in vivo neuronal transfection. J Control Release. 2018;286(July):264–278. doi:10.1016/j.jconrel.2018.07.04330071253
   PubMedGoogle Scholar
• Sharma G, Modgil A, Sun C, Singh J. Grafting of cell-penetrating peptide to receptor-targeted liposomes improves their transfection efficiency and transport across blood-brain barrier model. J Pharm Sci. 2012;101(7):2468–2478. doi:10.1002/jps.2315222517732
   PubMedGoogle Scholar
• dos Santos Rodrigues B, Banerjee A, Kanekiyo T, Singh J. Functionalized liposomal nanoparticles for efficient gene delivery system to neuronal cell transfection. Int J Pharm. 2019;566(April):717–730. doi:10.1016/j.ijpharm.2019.06.02631202901
   PubMedGoogle Scholar
• Sharma G, Modgil A, Layek B, et al. Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: biodistribution and transfection. J Control Release. 2013;167(1):1–10. doi:10.1016/j.jconrel.2013.01.01623352910
   PubMedGoogle Scholar
• Sumners C, Fregly MJ. Modulation of angiotensin II binding sites in neuronal cultures by mineralocorticoids. Am J Physiol. 1989;256:C121–C129. doi:10.1152/ajpcell.1989.256.1.C1212912130
   PubMedGoogle Scholar
• Layek B, Haldar MK, Sharma G, Lipp L, Mallik S, Singh J. Hexanoic acid and polyethylene glycol double grafted amphiphilic chitosan for enhanced gene delivery: influence of hydrophobic and hydrophilic substitution degree. Mol Pharm. 2014;11(3):982–994. doi:10.1021/mp400633r24499512
   PubMedGoogle Scholar
• Nakagawa S, Deli MA, Kawaguchi H, et al. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int. 2009;54(3–4):253–263. doi:10.1016/j.neuint.2008.12.00219111869
   PubMed Web of Science ®Google Scholar
• Helms HC, Abbott NJ, Burek M, et al. In vitro models of the blood–brain barrier: an overview of commonly used brain endothelial cell culture models and guidelines for their use. J Cereb Blood Flow Metab. 2016;36(5):862–890. doi:10.1177/0271678X1663099126868179
   PubMed Web of Science ®Google Scholar
• Xue Q, Liu Y, Qi H, et al. A novel brain neurovascular unit model with neurons, astrocytes and microvascular endothelial cells of rat. Int J Biol Sci. 2013;9(2):174–189. doi:10.7150/ijbs.511523412420
   PubMedGoogle Scholar
• Balbino TA, Gasperini AAM, Oliveira CLP, Azzoni AR, Cavalcanti LP, De La Torre LG. Correlation of the physicochemical and structural properties of pDNA/cationic liposome complexes with their in vitro transfection. Langmuir. 2012;28(31):11535–11545. doi:10.1021/la302608g22788539
   PubMedGoogle Scholar
• Kim BK, Hwang GB, Seu YB, Choi JS, Jin KS, Doh KO. DOTAP/DOPE ratio and cell type determine transfection efficiency with DOTAP-liposomes. Biochim Biophys Acta - Biomembr. 2015;1848(10):1996–2001. doi:10.1016/j.bbamem.2015.06.020
   Web of Science ®Google Scholar
• Ciani L, Ristori S, Salvati A, Calamai L, Martini G. DOTAP/DOPE and DC-Chol/DOPE lipoplexes for gene delivery: zeta potential measurements and electron spin resonance spectra. Biochim Biophys Acta - Biomembr. 2004;1664(1):70–79. doi:10.1016/j.bbamem.2004.04.003
   Web of Science ®Google Scholar
• Kolašinac R, Kleusch C, Braun T, Merkel R, Csiszár A. Deciphering the functional composition of fusogenic liposomes. Int J Mol Sci. 2018;19:2. doi:10.3390/ijms19020346
   Web of Science ®Google Scholar
• Nakamura K, Yamashita K, Itoh Y, Yoshino K, Nozawa S, Kasukawa H. Biochimica et biophysica acta comparative studies of polyethylene glycol-modi fi ed liposomes prepared using different PEG-modi fi cation methods. BBA - Biomembr. 2012;1818(11):2801–2807. doi:10.1016/j.bbamem.2012.06.019
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release. 2010;145(3):178–181. doi:10.1016/j.jconrel.2010.03.01620338200
   PubMed Web of Science ®Google Scholar
• Kang JH, Jang WY, Ko YT. The effect of surface charges on the cellular uptake of liposomes investigated by live cell imaging. Pharm Res. 2017;34(4):704–717. doi:10.1007/s11095-017-2097-328078484
   PubMed Web of Science ®Google Scholar
• Lee S, Sato Y, Hyodo M, Harashima H. Topology of surface ligands on liposomes : characterization based on the terms, incorporation ratio, surface anchor density, and reaction yield. Biol Pharm Bull. 2016;39(12):1983–1994. doi:10.1248/bpb.b16-0046227904040
   PubMedGoogle Scholar
• Elmquist A, Lindgren M, Bartfai T, Langel U. VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. Exp Cell Res. 2001;269(2):237–244. doi:10.1006/excr.2001.531611570816
   PubMed Web of Science ®Google Scholar
• Akdag IO, Ozkirimli E. The uptake mechanism of the cell-penetrating pVEC peptide. J Chem. 2013;2013. doi:10.1155/2013/851915
   Web of Science ®Google Scholar
• Kang S, Suresh A, Kim YC. A highly efficient cell penetrating peptide pVEC-mediated protein delivery system into microalgae. Algal Res. 2017;24(May):360–367. doi:10.1016/j.algal.2017.04.022
   Google Scholar
• Elmquist A, Hansen M, Langel U. Structure-activity relationship study of the cell-penetrating peptide pVEC. Biochim Biophys Acta. 2006;1758(6):721–729. doi:10.1016/j.bbamem.2006.05.01316808894
   PubMed Web of Science ®Google Scholar
• Yamano S, Dai J, Yuvienco C, Khapli S, Moursi AM, Montclare JK. Modified Tat peptide with cationic lipids enhances gene transfection efficiency via temperature-dependent and caveolae-mediated endocytosis. J Control Release. 2011;152(2):278–285. doi:10.1016/j.jconrel.2011.02.00421315780
   PubMedGoogle Scholar
• Yuan M, Qiu Y, Zhang L, Gao H, He Q. Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma. Drug Deliv. 2016;23(4):1171–1183. doi:10.3109/10717544.2015.104052726036724
   PubMed Web of Science ®Google Scholar
• Richard JP, Melikov K, Brooks H, Prevot P, Lebleu B, Chernomordik LV. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem. 2005;280(15):15300–15306. doi:10.1074/jbc.M40160420015687490
   PubMed Web of Science ®Google Scholar
• Johnsen KB, Moos T. Revisiting nanoparticle technology for blood-brain barrier transport: unfolding at the endothelial gate improves the fate of transferrin receptor-targeted liposomes. J Control Release. 2016;222:32–46. doi:10.1016/j.jconrel.2015.11.03226658072
   PubMed Web of Science ®Google Scholar
• Jobin ML, Alves ID. On the importance of electrostatic interactions between cell penetrating peptides and membranes: a pathway toward tumor cell selectivity? Biochimie. 2014;107(Part A):154–159. doi:10.1016/j.biochi.2014.07.02225107405
   PubMedGoogle Scholar
• Mo RH, Zaro JL, Shen WC. Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy. Mol Pharm. 2012;9(2):299–309. doi:10.1021/mp200481g22171592
   PubMedGoogle Scholar
• Erazo-Oliveras A, Muthukrishnan N, Baker R, Wang TY, Pellois JP. Improving the endosomal escape of cell-penetrating peptides and their cargos: strategies and challenges. Pharmaceuticals. 2012;5(11):1177–1209. doi:10.3390/ph511117724223492
   PubMedGoogle Scholar
• Tashima T. Intelligent substance delivery into cells using cell-penetrating peptides. Bioorganic Med Chem Lett. 2017;27(2):121–130. doi:10.1016/j.bmcl.2016.11.083
   PubMed Web of Science ®Google Scholar
• Trabulo S, Cardoso AL, Mano M, de Lima MCP. Cell-penetrating peptides-mechanisms of cellular uptake and generation of delivery systems. Pharmaceuticals. 2010;3(4):961–993. doi:10.3390/ph304096127713284
   PubMedGoogle Scholar
• Åmand HL, Rydberg HA, Fornander LH, Lincoln P, Nordén B, Esbjörner EK. Cell surface binding and uptake of arginine- and lysine-rich penetratin peptides in absence and presence of proteoglycans. Biochim Biophys Acta - Biomembr. 2012;1818(11):2669–2678. doi:10.1016/j.bbamem.2012.06.006
   PubMed Web of Science ®Google Scholar
• Yang ST, Zaitseva E, Chernomordik LV, Melikov K. Cell-penetrating peptide induces leaky fusion of liposomes containing late endosome-specific anionic lipid. Biophys J. 2010;99(8):2525–2533. doi:10.1016/j.bpj.2010.08.02920959093
   PubMed Web of Science ®Google Scholar
• Wilhelm I, Krizbai IA. In vitro models of the blood-brain barrier for the study of drug delivery to the brain. Mol Pharm. 2014;11(7):1949–1963. doi:10.1021/mp500046f24641309
   PubMedGoogle Scholar
• Aday S, Cecchelli R, Hallier-Vanuxeem D, Dehouck MP, Ferreira L. Stem cell-based human blood-brain barrier models for drug discovery and delivery. Trends Biotechnol. 2016;34(5):382–393. doi:10.1016/j.tibtech.2016.01.00126838094
   PubMed Web of Science ®Google Scholar
• Gerets HHJ, Hanon E, Cornet M, et al. Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach. Toxicol Vitr. 2009;23(2):319–332. doi:10.1016/j.tiv.2008.11.012
   PubMed Web of Science ®Google Scholar
• Campion S, Aubrecht J, Boekelheide K, et al. The current status of biomarkers for predicting toxicity. Expert Opin Drug Metab Toxicol. 2013;9(11):1391–1408. doi:10.1517/17425255.2013.82717023961847
   PubMed Web of Science ®Google Scholar
• Yao J, Fan Y, Li Y, Huang L. Strategies on the nuclear-targeted delivery of genes. J Drug Target. 2013;21(10):926–939. doi: 10.3109/1061186X.2013.83031023964565
   PubMed Web of Science ®Google Scholar